Generated: May 29, 2017
|Title:||Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate|
|Abstract:||A method of reducing mortality associated with chronic congestive heart failure in a patient with impaired cardiac function and concomitant reduced exercise tolerance, comprising the oral administration to said patient in need of the same of a combination of (a) between about 75 and about 300 milligrams of hydralazine, per day and (b) between about 40 and about 160 milligrams of isosorbide dinitrate, per day.|
|Inventor(s):||Cohn; Jay N. (Minneapolis, MN)|
Patent Claim Types:|
see list of patent claims
|Use; Dosage form;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.